Sign Out
Pregnancy: There are no adequate and well-controlled study data in pregnant women. Verapamil crosses the placenta and has been measured in umbilical cord blood. Verapamil hydrochloride should not be given during pregnancy (especially in the first trimester) unless, in the physician's judgement, it is essential for the patient's well-being (see Pharmacology: Toxicology: Preclinical safety data under Actions).
Lactation: Verapamil crosses the placental barrier and can be detected in umbilical vein blood at delivery. Verapamil hydrochloride/metabolites are excreted in human milk. Limited human data from oral administration has shown that the infant relative dose of verapamil is low (0.1-1% of the mother's oral dose). A risk to the newborns/infants cannot be excluded. Due to the potential for serious adverse reactions in nursing infants, verapamil should only be used during lactation if it is essential for the welfare of the mother.
